Clinical Trial Update: Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating Chimeric Natural Killer Receptor-Universal T Cells for refractory graft-versus-host disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Chimeric Natural Killer Receptor-Universal T Cells

Snippet

Sponsor: Fujian Medical University | Conditions: Graft vs Host Disease | Phase 1 | Status: RECRUITING